Description
CINK4 is a triaminopyrimidine derivative that inhibits Cdk4/cyclin D1 and Cdk6/cyclin D1 activity with IC₅₀ values of 1.5 and 5.6 μM, respectively. It reduces retinoblastoma protein phosphorylation at Ser780 and Ser795 and induces cell cycle arrest in the G1 phase in U2OS and MRC-5 cells at 5-10 µM. Administration of CINK4 at 30 mg/kg, i.p. for 29 days, suppresses tumor growth in mice bearing human HCT116 colon carcinoma xenografts.
CINK4 is a triaminopyrimidine derivative that inhibits Cdk4/cyclin D1 and Cdk6/cyclin D1 activity with IC₅₀ values of 1.5 and 5.6 μM, respectively. It reduces retinoblastoma protein phosphorylation at Ser780 and Ser795 and induces cell cycle arrest in the G1 phase in U2OS and MRC-5 cells at 5-10 µM. Administration of CINK4 at 30 mg/kg, i.p. for 29 days, suppresses tumor growth in mice bearing human HCT116 colon carcinoma xenografts.
Alternate Name/Synonyms: trans-4-[[6-(Ethylamino)-2-[[1-(phenylmethyl)-1H-indol-5-yl]amino]-4-pyrimidinyl]amino]-cyclohexanol; 4-[[2-[(1-benzylindol-5-yl)amino]-6-(ethylamino)pyrimidin-4-yl]amino]cyclohexan-1-ol; Cdk4/6 Inhibitor IV
Appearance: A crystalline solid
Formulation:
CAS Number: 359886-84-3
Structure Available?: True
Peptide sequence:
Salt Form: false
Molecular Formula: C₂₇H₃₂N₆O
Molecular Weight: 456.58
Cell-Permeable?: True
Purity: 95%
Solubilities: ~1 mg/ml in in Ethanol, ~30 mg/ml in DMSO and DMF in 0
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A Cdk4/6 inhibitor
MDL Number:
PubChem CID: 24825971
SMILES: CCNC1=CC(=NC(=N1)NC2=CC3=C(C=C2)N(C=C3)CC4=CC=CC=C4)NC5CCC(CC5)O
InChi: InChI=1S/C27H32N6O/c1-2-28-25-17-26(29-21-8-11-23(34)12-9-21)32-27(31-25)30-22-10-13-24-20(16-22)14-15-33(24)18-19-6-4-3-5-7-19/h3-7,10,13-17,21,23,34H,2,8-9,11-12,18H2,1H3,(H3,28,29,30,31,32)
InChi Key: YVXCDLCJCIDFHE-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
RT |
Shelf Life: |
36 months |